Form 4: MiniMed CEO Acquires 621,563 Shares Post-Medtronic Split

MiniMed Group, Inc. CEO Que Dallara acquired 621,563 restricted stock units following the company's separation from Medtronic plc.

Summary

• Que Dallara, Chief Executive Officer and Director of MiniMed Group, Inc. (MMED), acquired a total of 621,563 shares of common stock in the form of Restricted Stock Units (RSUs) on March 11, 2026.
• These acquisitions resulted from the conversion of certain restricted stock units and performance share units previously granted by Medtronic plc ('Medtronic Awards') into MMED RSUs.
• The conversion was a direct consequence of MMED's separation from Medtronic plc, which became effective on March 9, 2026.
• The terms of the conversion were governed by an Employee Matters Agreement (EMA) dated March 1, 2026, between Medtronic Group Holding, Inc. and Kangaroo US HoldCo 2, Inc.
• The conversion ratio was determined based on the average closing trading prices of Medtronic ordinary shares for the three trading days ending March 6, 2026, and MMED common stock for the three trading days starting March 9, 2026.
• The newly granted MMED RSUs are subject to various time-based vesting schedules, with dates ranging from July 31, 2026, to July 28, 2028, and are issued under the 2026 MiniMed Group, Inc. Long Term Incentive Plan (LTIP).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive, routine event, as it aligns executive incentives with the newly independent company's long-term performance, which is a standard and healthy practice post-spin-off.

Positives

• The acquisition of a significant number of restricted stock units by the CEO increases her direct equity interest in MiniMed Group, Inc., aligning her incentives with long-term shareholder value.
• The conversion of Medtronic Awards into MMED RSUs ensures continuity of executive compensation and retention following the spin-off, which is crucial for stable leadership.
• The establishment of the 2026 MiniMed Group, Inc. Long Term Incentive Plan (LTIP) demonstrates a structured approach to executive compensation and performance incentives for the newly independent company.

Future Outlook

The future outlook for the CEO's equity compensation is tied to the vesting schedules of the newly granted MMED RSUs, which extend through July 2028, indicating a long-term commitment to the company's performance.

Industry Context

StockSavvy.ai notes that corporate spin-offs frequently involve complex restructuring of executive equity awards. This conversion of Medtronic awards into MiniMed RSUs is a standard mechanism to ensure that key executives, such as the CEO, maintain strong incentives aligned with the performance of the newly independent entity, thereby promoting leadership stability and long-term value creation post-separation.

Comparison to Industry Standards

• This type of equity award conversion is a common practice in major corporate spin-offs, mirroring actions taken by companies like GE when it spun off GE HealthCare, or Johnson & Johnson with Kenvue.
• The use of an Employee Matters Agreement (EMA) to govern the conversion terms is standard for ensuring a smooth transition of employee benefits and compensation structures between the parent and the spun-off entity.
• The establishment of a new Long Term Incentive Plan (LTIP) for the independent company, under which these RSUs are granted, aligns with best practices for public companies to attract, retain, and motivate executive talent through performance-based compensation.

Corporate Governance

Related Party Transactions

• The conversion of Medtronic Awards into MMED RSUs is a transaction stemming from the separation of MiniMed Group, Inc. from its former parent, Medtronic plc, governed by the Employee Matters Agreement.

Stakeholder Impact

• Shareholders: Benefit from increased alignment of executive incentives with the company's long-term performance, potentially leading to better governance and strategic decisions.
• Employees: The continuity of equity awards, albeit in a converted form, helps retain key talent and ensures their long-term commitment to the new entity.

Next Steps

• Vesting of 57,239 MMED RSUs on July 31, 2026.
• Vesting of the second installment of 22,892 MMED RSUs on March 10, 2027.
• Vesting of 281,937 MMED RSUs on April 30, 2027.
• Vesting of 80,842 MMED RSUs on July 29, 2027.
• Vesting of 127,609 MMED RSUs on April 28, 2028.
• Vesting of 51,044 MMED RSUs on July 28, 2028.

Key Dates

Recommendation

This Form 4 reports a routine conversion of executive equity awards following a corporate spin-off, which is a standard mechanism to maintain executive incentives. It does not provide new information that would significantly alter the investment thesis for MiniMed Group, Inc., thus a 'hold' recommendation is appropriate based solely on this filing.

Keywords

MiniMed Group, MMED, Medtronic, Spin-off, Restricted Stock Units, RSU, Insider Ownership, Executive Compensation, Equity Award Conversion, Que Dallara, Form 4